1. Home
  2. BKE vs STOK Comparison

BKE vs STOK Comparison

Compare BKE & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buckle Inc. (The)

BKE

Buckle Inc. (The)

HOLD

Current Price

$45.48

Market Cap

2.2B

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$32.12

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKE
STOK
Founded
1948
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
BKE
STOK
Price
$45.48
$32.12
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$53.00
$39.20
AVG Volume (30 Days)
447.3K
617.0K
Earning Date
05-22-2026
05-08-2026
Dividend Yield
7.96%
N/A
EPS Growth
6.43
92.73
EPS
0.92
N/A
Revenue
$1,297,835,000.00
$184,420,000.00
Revenue This Year
$5.10
N/A
Revenue Next Year
$4.99
$77.49
P/E Ratio
$49.55
N/A
Revenue Growth
6.58
404.50
52 Week Low
$40.73
$12.86
52 Week High
$61.69
$40.22

Technical Indicators

Market Signals
Indicator
BKE
STOK
Relative Strength Index (RSI) 59.34 N/A
Support Level $41.15 N/A
Resistance Level $56.21 N/A
Average True Range (ATR) 1.09 0.00
MACD 0.45 0.00
Stochastic Oscillator 94.21 0.00

Price Performance

Historical Comparison
BKE
STOK

About BKE Buckle Inc. (The)

Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: